Experience life as part of one of the most successful locations for life science start-ups in Europe. If you are an early-career entrepreneur with a sustainable business proposition based on great science and have the imagination, creativity, and resilience to succeed, Accelerate@Babraham is the place for you.
Concentrated, intense, potentially life-changing
A competitive and rigorous selection process - only 5 will make it
12 months access to free lab space and support to stress test your science
Challenge and be challenged by those that have been there and done it before
No strings attached non-dilutive funding, spend it wisely!
Founded and developed at the Babraham Research Campus in 2018, Accelerate@Babraham, the Campus’ pre-seed company support programme, was created out of a desire to support and nurture early-stage life science ventures attempting to navigate this tough and fast-moving sector.
The programme, which each year offers five early-stage life science start-ups the chance to join the Babraham Research Campus community, brings to bear an unrivalled network of experts, mentors, investors, data-driven business support, lab space and funding to equip new enterprises with the skills, confidence, connections to enable success.
Want to know what life as part of Accelerate@Babraham is really like? We sat down with previous participants to understand just that. The resulting article and film will give you an insight into the value of the programme, the incredible team of partners and supporters that are involved in delivering it and the tangible successes achieved by our cohort companies.
Applications were invited from life science start-up companies working in therapeutics, reagents, technology platforms and diagnostics who would benefit from access to fully equipped, serviced lab and office space, business and technical support from practitioners, and the opportunity to expand their network and deeply embed in the outstanding Cambridge life science cluster.
In 2024, we were particularly interested in applications from companies with a focus on renal or cardiometabolic-related diseases, including diabetes, obesity, NASH, chronic kidney disease and cardiovascular disease.
Accelerate@Babraham wouldn’t exist without the commitment and support of a superb group of strategic supporters, all of whom dedicate time, resource, and funds to ensure the initiative is continually able to evolve and adapt to deliver the very best nurturing support, not only to the current cohort but also the alumni.
Over 60 individuals, all highly experienced in their respective fields, give their time freely in support of our next generation life science innovators. To date we’ve delivered over 130 bespoke training sessions, facilitated over 330 hours of round-table seminars and discussions, and made hundreds of personal introductions. Meet them here.
Now in its sixth year, Accelerate@Babraham has supported 26 early-stage enterprises and been recognised as one of the top 25 biotech incubators in Europe (LaBiotech, March 2021). To date, our alumni has raised £46.8M and has a current portfolio value estimated at over £90M. We proudly shout about their successes and achievements whenever and wherever we can!
Precisio Biotix Therapeutics Acquires London-Headquartered CC Bio, Adding World-Class Antibacterial Platform and Top Scientists
Biotech start-up BugBiome secures investment for pioneering research in sustainable pest protection
Neobe Therapeutics Raises Over $2m For Synthetic Biology Enabled Tumour Microenvironment Remodelling
